Non-PEGylated Liposomal Azithromycin for Post-MI Cardiac Recovery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapeutic agents for treating post-myocardial infarction remodeling suffer from limited efficacy due to poor bioavailability in the heart and dose-limiting adverse effects, failing to effectively address the inflammatory response and cardiac remodeling post-infarction.
Innovation Solution
A non-PEGylated liposomal azithromycin formulation that accumulates in the injured myocardium, shifting macrophage polarization towards the reparative phenotype, reducing pro-inflammatory macrophages, and increasing anti-inflammatory macrophages, thereby modulating the inflammatory response and promoting cardiac recovery.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If therapeutic agents are administered systemically to treat post-MI remodeling, then the inflammatory response can be addressed, but the agents suffer from poor bioavailability in the heart and dose-limiting adverse effects
Solution Approach 1:
The patent uses liposomes as intermediary carriers to deliver azithromycin to the heart. The liposomal formulation acts as a mediator between the therapeutic agent and the target tissue, enabling targeted delivery while reducing systemic exposure and adverse effects. The liposomes accumulate preferentially in the injured myocardium, delivering the anti-inflammatory agent directly to where it is needed.
Solution Approach 2:
The patent modifies the physical and chemical parameters of the therapeutic delivery system by encapsulating azithromycin in liposomes. This changes the pharmacokinetic parameters including bioavailability, half-life, and tissue distribution. The liposomal formulation alters the drug's ability to reach the heart while minimizing systemic adverse effects.
2Reliability
If higher doses of therapeutic agents are used to overcome poor bioavailability, then cardiac recovery may be improved, but dose-limiting adverse effects increase
Solution Approach 1:
The liposomal formulation serves as an intermediary that enables effective cardiac delivery without requiring high systemic doses. The targeted accumulation of liposomes in the injured myocardium allows sufficient drug concentration at the site of injury while maintaining lower overall dosages that avoid dose-limiting adverse effects.
Solution Approach 2:
The patent achieves local concentration of the therapeutic agent in the injured myocardium through liposomal targeting. This creates a local quality difference where high drug concentration exists specifically in the heart tissue that needs treatment, while systemic concentrations remain low enough to avoid adverse effects.
Data Source
AI summary
A composition and method for treating a subject following myocardial infarction are provided. The composition includes a non-PEGylated liposome. The method includes administering a non-PEGylated liposome to a subject in need thereof following myocardial infarction.